Moreover, exploring the effects of therapies known to target genetic aberrations [such as spliceosome inhibitors (114)] or the microenvironment [such as luspatercept, an inhibitor of transforming growth factor beta that can neutralize negative regulators of late-stage erythropoiesis (117)] in SF3B1-mutated MDS may offer insights into the connection between these factors. The gene discussed is SF3B1; the disease is myelodysplastic syndrome.